➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Boehringer Ingelheim
McKesson
Medtronic
Johnson and Johnson

Last Updated: November 28, 2020

DrugPatentWatch Database Preview

Claims for Patent: 7,601,746

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,601,746
Title:Compounds exhibiting thrombopoietin receptor agonism
Abstract: A compound represented by the general formula (I): ##STR00001## wherein R.sup.1 is a hydrogen atom, a halogen atom, or the like; R.sup.2, R.sup.3, and R.sup.4 are each independently a hydrogen atom, a halogen atom, C1-C15 alkyl optionally substituted with one or more C1-C12 alkyloxy or the like, or the like; R.sup.5 is a hydrogen atom or the like; R.sup.6 and R.sup.7 are a hydrogen atom or the like; R.sup.8 is C1-C3 alkyl or the like; R.sup.9 is a hydrogen atom or the like), a prodrug, a pharmaceutically acceptable salt, or solvate thereof.
Inventor(s): Takayama; Masami (Osaka, JP), Yoshida; Yutaka (Osaka, JP)
Assignee: Shionogi & Co., Ltd. (Osaka, JP)
Application Number:10/567,993
Patent Claims: 1. A compound represented by the general formula (I): ##STR00016## wherein R.sup.1 is a hydrogen atom, halogen atom, C1-C6 alkyl, or C1-C12 alkyloxy; R.sup.2, R.sup.3, and R.sup.4 are each independently a hydrogen atom, a halogen atom, C1-C15 alkyl optionally substituted with one or two substituent(s) selected from substituent group A, C2-C15 alkenyl optionally substituted with one or two substituent(s) selected from substituent group A, C2-C15 alkynyl optionally substituted with one or two substituent(s) selected from substituent group A, C3-C8 cycloalkyl, C1-C15 alkyloxy optionally substituted with one or two substituent(s) selected from substituent group A, or phenyl optionally substituted with one or two substituent(s) selected from substituent group A; R.sup.5 is a hydrogen atom, a halogen atom, C1-C3 alkyl, or C1-C3 alkyloxy; R.sup.6 is a hydrogen atom, a halogen atom, or C1-C3 alkyl; R.sup.7 is a halogen atom or C1-C3 alkyl; R.sup.8 is a halogen atom, C1-C3 alkyl, or C1-C3 alkyloxy; R.sup.9 is a hydrogen atom or C1-C6 alkyl; or R.sup.1 and R.sup.5 are taken together with the adjacent carbon atoms may form a 5 to 8 membered ring which may contain a heteroatom and/or an unsaturated bond, wherein the ring may be substituted with one or two C1-C8 alkyl; provided that when R.sup.2 and R.sup.3 are a chlorine atom, R.sup.6 is not a hydrogen atom; substituent group A consists of halogen atom, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, phenyl, naphthyl, pyridyl, oxolanyl, cyano, C1-C12 alkyloxy, C2-C12 alkenyloxy, C2-C12 alkynyloxy, C3-C8 cycloalkyl-C1-C8 alkyloxy, phenyl-C1-C8 alkyloxy, naphthyl-C1-C8 alkyloxy, C1-C8 alkyloxy-C1-C8 alkyloxy, (C1-C8 alkyloxy-C1-C8 alkyloxy)C1-C8 alkyloxy, di(C1-C8 alkyloxy)C1-C8 alkyloxy, oxolanyl-C1-C8 alkyloxy, haloC1-C8 alkyloxy, C3-C8 cycloalkyloxy, amino optionally substituted with C1-C8 alkyl, C1-C8 alkylthio, and C1-C8 alkylthio-C1-C8 alkyloxy; a pharmaceutically acceptable salt, or solvate thereof.

2. A compound of claim 1, wherein both of R.sup.6 and R.sup.7 are fluorine atom or chlorine atom, a pharmaceutically acceptable salt, or solvate thereof.

3. A compound of claim 1, wherein R.sup.5 is a hydrogen atom or C1-C3 alkyloxy, a pharmaceutically acceptable salt, or solvate thereof.

4. A compound of claim 1, wherein R.sup.8 is methyl or methyloxy, a pharmaceutically acceptable salt, or solvate thereof.

5. A compound of any one of claims 1 to 4, wherein R.sup.2 is C1-C15 alkyl optionally substituted with one or two substituent(s) selected from substituent group A, C2-C15 alkynyl optionally substituted with one or two substituent(s) selected from substituent group A, or C1-C15 alkyloxy optionally substituted with one or two substituent(s) selected from substituent group A, a pharmaceutically acceptable salt, or solvate thereof.

6. A compound of any one of claims 1 to 4, wherein R.sup.2 is C1-C12 alkyl optionally substituted with one or two C1-C8 alkyloxy, and both of R.sup.3 and R.sup.4 are a hydrogen atom, a pharmaceutically acceptable salt, or solvate thereof.

7. A compound represented by the general formula (II): ##STR00017## wherein R.sup.A is a hydrogen atom, C1-C12 alkyloxy, C1-C8 alkyloxy-C1-C8 alkyloxy or (C1-C8 alkyloxy-C1-C8 alkyloxy)C1-C8 alkyloxy; R.sup.B is C1-C14 alkyl optionally substituted with one or two substituent(s) selected from substituent group B, C2-C14 alkynyl optionally substituted with one or two substituent(s) selected from substituent group B, C3-C8 cycloalkyl, C1-C14 alkyloxy optionally substituted with one or two substituent(s) selected from substituent group B, phenyl, or naphthyl; R.sup.C is a hydrogen atom, halogen atom, C1-C6 alkyl, or C1-C12 alkyloxy; R.sup.D is a hydrogen atom, halogen atom, C1-C3 alkyl, or C1-C3 alkyloxy; R.sup.6 and R.sup.7 are each independently halogen atom or C1-C3 alkyl; R.sup.8 is halogen atom, C1-C3 alkyl, or C1-C3 alkyloxy; substituent group B consists of halogen atom, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, phenyl, naphthyl, pyridyl, oxolanyl, cyano, C1-C8 alkyloxy, C2-C8 alkenyloxy, C2-C8 alkynyloxy, C3-C8 cycloalkyl-C1-C8 alkyloxy, phenyl-C1-C8 alkyloxy, naphthyl-C1-C8 alkyloxy, C1-C8 alkyloxy-C1-C8 alkyloxy, (C1-C8 alkyloxy-C1-C8 alkyloxy)C1-C8 alkyloxy, di(C1-C8 alkyloxy)C1-C8 alkyloxy, oxolanyl-C1-C8 alkyloxy, haloC1-C8 alkyloxy, C3-C8 cycloalkyloxy, amino optionally substituted with C1-C8 alkyl, C1-C8 alkylthio, and C1-C8 alkylthio-C1-C8 alkyloxy; a pharmaceutically acceptable salt, or solvate thereof.

8. A compound of claim 7, wherein both of R.sup.6 and R.sup.7 are fluorine atom or chlorine atom, a pharmaceutically acceptable salt, or solvate thereof.

9. A compound of claim 7, wherein R.sup.8 is methyl or methyloxy, a pharmaceutically acceptable salt, or solvate thereof.

10. A compound of claim 7, wherein R.sup.C is fluorine atom or C1-C3 alkyloxy, a pharmaceutically acceptable salt, or solvate thereof.

11. A compound of any one of claims 7 to 10, wherein R.sup.A is C1-C8 alkyloxy; R.sup.B is C1-C11 alkyl optionally substituted with one or two substituent(s) selected from substituent group B, or C2-C11 alkynyl optionally substituted with one or two substituent(s) selected from substituent group B, a pharmaceutically acceptable salt, or solvate thereof.

12. A compound of claim 7, wherein R.sup.C is fluorine atom or C1-C3 alkyloxy, R.sup.D is a hydrogen atom or C1-C3 alkyloxy, both of R.sup.6 and R.sup.7 are fluorine atom or chlorine atom, R.sup.8 is methyl or methyloxy, R.sup.A is C1-C3 alkyloxy, R.sup.B is C8-C12 alkyl optionally substituted with one or two substituent(s) selected from substituent group B, a pharmaceutically acceptable salt, or solvate thereof.

13. A compound represented by the general formula (II-A): ##STR00018## wherein R.sup.C is a hydrogen atom, a halogen atom, C1-C6 alkyl, or C1-C12 alkyloxy; R.sup.D is a hydrogen atom, a halogen atom, C1-C3 alkyl, or C1-C3 alkyloxy; R.sup.F is C1-C14 alkyl optionally substituted with one or two substituent(s) selected from substituent group D, C2-C14 alkenyl optionally substituted with one or two substituent(s) selected from substituent group D, C2-C14 alkynyl optionally substituted with one or two substituent(s) selected from substituent group D, C1-C14 alkyloxy optionally substituted with one or two substituent(s) selected from substituent group C, C3-C8 cycloalkyl, or phenyl optionally substituted with one or two substituent(s) selected from substituent group D; R.sup.6 and R.sup.7 are each independently halogen atom or C1-C3 alkyl; R.sup.8 is halogen atom, C1-C3 alkyl, or C1-C3 alkyloxy; substituent group D consists of halogen atom, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, phenyl, naphthyl, pyridyl, oxolanyl, cyano, C1-C8 alkyloxy, C2-C8 alkenyloxy, C2-C8 alkynyloxy, C3-C8 cycloalkyl-C1-C8 alkyloxy, phenyl-C1-C8 alkyloxy, naphthyl-C1-C8 alkyloxy, C1-C8 alkyloxy-C1-C8 alkyloxy, (C1-C8 alkyloxy-C1-C8 alkyloxy)C1-C8 alkyloxy, di(C1-C8 alkyloxy)C1-C8 alkyloxy, oxolanyl-C1-C8 alkyloxy, haloC1-C8 alkyloxy, C3-C8 cycloalkyloxy, amino optionally substituted with C1-C8 alkyl, C1-C8 alkylthio, and C1-C8 alkylthio-C1-C8 alkyloxy; a pharmaceutically acceptable salt, or solvate thereof.

14. A compound of claim 13, wherein both of R.sup.6 and R.sup.7 are fluorine atom or chlorine atom, a pharmaceutically acceptable salt, or solvate thereof.

15. A compound of claim 13, wherein R.sup.8 is methyl or methyloxy, a pharmaceutically acceptable salt, or solvate thereof.

16. A compound of claim 13, wherein R.sup.C is fluorine atom or C1-C3 alkyloxy, a pharmaceutically acceptable salt, or solvate thereof.

17. A compound of any one of claims 13 to 16, wherein R.sup.F is C1-C14 alkyl optionally substituted with one or two substituent(s) selected from substituent group D, C2-C14 alkynyl optionally substituted with one or two substituent(s) selected from substituent group D, or C1-C14 alkyloxy optionally substituted with one or two substituent(s) selected from substituent group D, a pharmaceutically acceptable salt, or solvate thereof.

18. A pharmaceutical composition containing a compound as an active ingredient, a pharmaceutically acceptable salt, or solvate thereof of any one of claims 1 to 4, 7 to 10, or 13 to 16.

19. A pharmaceutical composition containing a compound as an active ingredient, a pharmaceutically acceptable salt, or solvate thereof of any one of claims 1 to 4, 7 to 10, or 13 to 16 in an amount effective for exhibiting thrombopoietin receptor agonism.

20. A pharmaceutical composition containing a compound as an active ingredient, a pharmaceutically acceptable salt, or solvate thereof of any one of claims 1 to 4, 7 to 10, or 13 to 16 in an amount effective for modifying platelet production.

21. A method for treating or preventing hemopathy in a mammal, including a human, in need thereof, comprising administering to said mammal a compound, a pharmaceutically acceptable salt, or solvate thereof of any one of claims 1 to 4, 7 to 10, or 13 to 16 in an amount effective amount for modifying platelet production.

22. A compound of claim 1, wherein the compound is ##STR00019## or a pharmaceutically acceptable saft thereof.

23. A compound of claim 1, wherein the compound is ##STR00020## or a pharmaceutically acceptable salt thereof.

24. A compound of claim 1, wherein the compound is ##STR00021## or a pharmaceutically acceptable salt thereof.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Merck
Mallinckrodt
Johnson and Johnson
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.